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Background and aim: The Greater Poland Region is one of the most industrialised areas of
Poland, with a high rate of cancer incidence and mortality. The present report estimated
incidence and mortality data for Greater Poland in the year 2010.
Methods: Statistical reports in this study include absolute number of cases and crude inci-
dence rates. The derived age-, sex-, and site speciﬁc rates were age-standardised (ASRs per
100,000 person-years) using the European (ASRE) standard population.
Results: In 2010, a total 13,581 new cancer cases were reported to the Greater Poland Cancer
Registry. The number of new cases increased by 24% compared to 2001. Greater Poland has
the  second-highest ASR for both females and males among the 16 regions in Poland. The
most common cancers are similar to those in other Western European countries. Among
men, the most common cancers are lung (C34), colorectal (C18-C21), and prostate (C61)
cancer. In women, breast cancer is the most common (C50), followed by colon (C18-C21)
and  lung (C34) cancer. Lung cancer in males accounts for more than one-third of all cancer-
related deaths in Greater Poland. As in 2009, lung cancer is the leading cause of death in
women.
Conclusions: Given the ageing of the population, the incidence of chronic diseases, including
cancer, is expected to grow. These data indicate that cancer will continue to represent animportant challenge both to local health authorities and the National Health Fund, which
will  need to meet the growing demand for cancer care.
© 2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.∗ Corresponding author at: Maria Skłodowska-Curie Memorial Greater P
fax:  +48 618850 916.
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.  Introduction
he incidence of cancer continues to rise in Europe as a
onsequence of population ageing, lifestyle choices (tobacco
nd alcohol use, physical inactivity, poor diet) and industrial
ontamination.1 While the incidence of cancer varies from
ountry to country, the incidence rates in Eastern Europe are
enerally higher than in those observed in Western Europe.1–5
Treating cancer is an expensive proposition requiring
ophisticated technology and costly chemotherapy agents and
argeted drugs. The most cost-effective approach to cancer
ontrol is, therefore, not treatment, but rather early detection
nd prevention.6 Prevention, however, also requires surveil-
ance through comprehensive cancer registries. Population-
ased registries provide valuable information on incidence
ates and trends in those rates based on tumour localization,
ex, and age. In addition, hospital-based registries provide
nformation regarding diagnosis, stage distribution, treatment
ethods and survival.
The Greater Poland Region is the second largest province
n Poland (29,825 km2) and the third most populous (3.4 mil-
ion inhabitants). Greater Poland consists of 31 administrative
istricts and 4 cities (Kalisz, Konin, Leszno, Poznan´) that func-
ion as their own district.7 Cancer surveillance in the region is
arried out by the Greater Poland Cancer Registry (GPCR). The
ncidence to mortality (I/M) ratio—an indicator of accuracy—of
he GPCR is 99%, thus making the GPCR among the most accu-
ate cancer registries in Poland.
The aim of the present report is to provide and discuss data
n cancer incidence in the Greater Poland Region for the year
010.
.  Materials  and  methods
ata for this descriptive study was obtained from the GPCR.
his cancer registry has been registering cancer cases in
oznan´, Poland since 1980, and for the province since 1985.
The GPCR has been member of the International Associ-
tion of Cancer Registries since 2008.4 According to the data
rom the National Cancer Registry for 2010, the GPCR, with a
egistration completeness of 99% (vs. a mean of 90% in Poland
s a whole), registration quality of 85% (vs. 84%) is one of the
ighest-quality regional cancer registries in Poland. The GPCR
ncludes data from 31 districts and 4 cities with “district rights”
Table 1 – Cancer incidence, Greater Poland, 2001–2010.
Year Male 
Absolute number Crude rate ASRE
2001 5367 330.8 395.26 
2002 5584 343.6 397.00 
2003 5749 353.4 405.33 
2004 5908 362.6 408.02 
2005 6340 388.5 409.52 
2006 6513 398.3 418.26 
2007 6749 412.0 421.51 
2008 7086 431.3 435.28 
2009 6964 422.4 419.77 
2010 6722 405.2 416.50 therapy 1 9 ( 2 0 1 4 ) 296–300 297
(Kalisz, Konin, Leszno, Poznan´). Since January 1, 2009, Death
Certiﬁcate Statistical Cards—which provide essential informa-
tion related to the patients cause of death—have been sent
electronically from all registering points in the country only to
a designated Statistical Ofﬁce in Olsztyn. As a result, this com-
prehensive information is no longer sent directly to regional
cancer registries.
Cancer registration is regulated by Polish law, including the
June 29, 1995 law on public statistics (Journal of Laws, 1995, No.
88, item 439, as amended) and the Council of Ministers “Reg-
ulation of Statistical Surveys of the Public Statistics” (Journal
of Laws of 2010, No. 3, item 14). All cancer registries in Poland
collect data, which is reported on the ofﬁcial form entitled the
“Cancer Notiﬁcation Form”. All tumours are coded according
to the 10th Revision of the International Classiﬁcation of Dis-
eases and Related Health Problems (ICD10). All malignancies
with the codes C00-C97, and in situ neoplasms (D00-D09) are
included in the registry.
Statistical reports in this study include absolute number
of cases, crude incidence rates. The derived age-, sex-, and
site speciﬁc rates were age-standardised (ASRs per 100,000
person-years) using the European (ASRE) standard population.
Females account for a majority of the population in the region,
with a male:female ratio of 100:106.
3.  Results
In 2010, 13,581 new cases of cancer were reported to the
GPCR (6722 men  and 6859 women). The number of new cases
increased by 2655 (24%) compared to 2001 (see Table 1). The
growth in cancer incidence increased proportionally by age
group.
The most common cancers in men  were lung (C34),
prostate (C61), and colon (C18). In women, the most common
locations were breast (C50), lung (C34), and corpus uteri (not
cervix) (C54) (see Fig. 1).
The total number of all in situ cancers (D00-D09, pre-
invasive, stage ‘0’) increased from 216 cases in 2005 to 183
cases in 2006, 278 in 2007, 308 in 2008, 327 in 2009, and 359
in the year 2010.
In 2010, 588 cancer cases (C00-D09) were identiﬁed by rou-
tine screening tests; this represents an increase of 227 (63%)
more cases than in 2009. Of these, 510 (87%) were breast
Female
Absolute number Crude rate ASRE
5559 323.2 299.37
5616 326.0 292.60
5722 331.7 294.00
5770 333.9 294.53
6282 362.8 304.28
6178 356.1 296.91
6746 387.8 319.06
6714 384.8 309.49
6749 385.5 311.76
6859 389.6 324.27
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cancers, 34 lung cancers, 16 cervical cancers, 11 colorectal
cancers, and 17 prostate cancers.
In the Greater Poland Region, 106 children aged 0–19 were
diagnosed with cancer (the crude incidence rate in children is
14 cases per 100,000 population).
According to the Central Statistical Ofﬁce, 8218 cancer-
related deaths were registered in the region in 2010 (4603 in
men  and 3615 in women) representing an increase of nearly 8%
(Table 2). Distribution of cancer deaths by age groups increases
proportionally by age, as do incidence rates.
The leading causes of cancer deaths reported in 2010 in
men  were lung cancer (C34), prostate cancer (C61), and can-
cer of the colon (C18). The leading causes of cancer deaths
in women reported in 2010 were the same as those reported
in 20092: lung cancer (C34), followed by breast (C50), and
colon cancer (C18). The distribution of cancer-caused deaths
in males and females is shown in Fig. 2.
4.  Discussion
This study provides an overview of cancer incidence and
mortality in the Greater Poland Region. In 2010, 13,581
new cancer cases were reported to the GPCC: 6722 cases
in males (ASRE 416.5) and 6859 cases in females (ASRE
4324.3). Importantly, these incidence rates are lower than
rates in several other western European countries (exclud-
ing females in Spain), including Spain (449.9 and 264.5
ASRE in males and females, respectively), France (550.7
Table 2 – Cancer mortality 2001–2010, Greater Poland.
Year Male 
Absolute number Crude rate ASRE
2001 4178 255.8 315.04
2002 4193 258.0 314.17
2003 4266 262.3 313.37
2004 4550 279.3 329.70
2005 4345 266.2 309.35
2006 4572 279.6 317.57
2007 4570 279.0 309.07
2008 4606 280.4 305.26
2009 4545 275.7 294.33
2010 4603 277.5 289.55on in 2010, males and females, Greater Poland.
and 369.8, respectively), and Germany (463.2 and 344.5,
respectively).8 The number of new cases increased by 2655
(24%) as compared to 2001 (Table 1). The most prevalent
cancers in men  are those of the lung (C34), prostate (C61),
and colon (C18). In women, the most common locations
are breast (C50), lung (C34), and corpus uteri (C54) (see
Fig. 1).
In Greater Poland, exposure to cancer risk is related to risk
agents (primarily tobacco smoke), and population ageing (the
number of males between age 50 and 69 increased by 31%
and females by 28% in the period from 2001 to 2010). In 2010,
the cancer registry recorded 8218 cancer related deaths (4603
men, 3615 women). In terms of the ASRE, the region has among
the highest ASRs among the 16 Polish provinces (2nd for both
sexes). Efforts to combat tobacco use have led to a decrease
in lung cancer, although this site still accounts for 19% of new
cases and 29% of deaths in the region. Prostate cancer is the
2nd most common cancer in men, and also shows the highest
growth rate.
The poor 5-year survival rates underscore the need for
more  research and effective prevention. To this end, in 2005,
efforts were initiated to expand the national cancer control
programme (National Cancer Combat Programme “Improve-
ment of the cancer data collection and registration system”)
to assess the level of public knowledge of health promot-
ing behaviours and to raise public awareness of cancer by
disseminating informational materials and organising media
campaigns to promote a healthy lifestyle.
Female
Absolute number Crude rate ASRE
 3408 197.6 175.33
 3391 196.8 171.86
 3329 193.0 165.38
 3407 197.2 166.54
 3540 204.4 169.58
 3679 212.0 174.18
 3710 213.3 171.59
 3573 204.8 160.48
 3713 212.1 164.88
 3615 205.3 156.22
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for Eastern European females, in whom rates are still ris-
ing. Similarly, incidence and mortality rates in women, whoFig. 2 – Distribution of cancer deaths in
The main challenges of Polish oncology are to improve
atient access to prompt diagnosis, followed by timely, com-
rehensive, and accurate treatment.9,10 To fulﬁl this aim,
dditional and regular investment in oncology hospitals
s necessary.11 Similarly, in order to gather reliable data,
mprovements in the r quality of cancer registration is
ssential.12 Early prevention plays a vital role in combating
ancer and should be linked with educational activities. How-
ver, despite the many  achievements made in recent years,
ne factor that has not been well-addressed, especially in the
ublic health sector, is patient comfort.13
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Fig. 3 – Predicted changes in canles and females, Greater Poland 2010.
Sound knowledge of the patterns of cancer incidence and
mortality is essential to establish policies for cancer control
among the various countries and regions of Europe. Inci-
dence rates for lung cancer in men  have began to decrease
in some European countries, particularly in those countries
(e.g., areas of North-Western Europe where smoking preva-
lence ﬁrst began to diminish). This is not, however, the caseacquired the smoking habit later than men, are now on the
rise in a number of European countries. Hence, lung cancer
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retains its status as the most common cancer in Europe,
as well as the leading cause of cancer death. The lessons
for primary prevention, through efforts to decrease tobacco
smoking, are obvious. Such measures will have an impact
upon other tobacco-related cancers too, including cancer of
the oral cavity and pharynx, oesophagus, pancreas, larynx and
urinary tract.
A reduction in alcohol consumption would reduce the
risk of neoplasms of the upper digestive system and respi-
ratory tract. Likewise, there is scope to prevent colorectal
and breast cancer—the second and third most common can-
cers in Europe, respectively—through diet modiﬁcation and,
particularly for breast cancer, by reducing the prevalence of
obesity. Compared to previous estimates,14 there is also clear
evidence that preventative interventions have had an impact
on cancer incidence and mortality, particularly in the more
afﬂuent countries. For instance, the decline in cervical cancer
observed in several of the Nordic countries can be attributed
to the effectiveness of national screening programmes. Sim-
ilarly, effective treatment of testicular tumours has led to a
reduction in death rates in many  European countries during
the last decade.
Cancer registries allow for the follow up of treatment
results.15 Moreover, evaluation of clinical results using cancer
registry data is not only limited to a particular institution but
instead enables us to perform inter-institutional comparison
between oncology hospitals.
The morbidity and mortality forecast for 2020, established
according to an exponential model based on data from 1999
to 2010, indicates that the GPCR will record 19,000 new cancer
cases (9810 in men  and 9145 in women), while 57,000 patients
will be under oncologist care (Fig. 3). Cancer-caused mortality
in 2020 is predicted to be 9500 (5253 men  and 4184 women).
The predicted increase in cancer incidence for Poland in
2019 is expected to result from demographic changes, the
inﬂuence of certain cancer risk factors, and participation in
screening programmes.15,16
5.  Conclusions
Population ageing combined with gradually increasing sur-
vival rates (due to improvements in diagnosing and treating
cancer patients) will require continuation of the anti-cancer
programmes in the Greater Poland province. This will neces-
sitate, therefore, ongoing investments to maintain and
modernise the infrastructure needed for treatment and diag-
nostics and funds to continue prevention programmes. Finally,
new funds will be needed to treat patients with newly
diagnosed cancers.
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